Statin use and all-cause and cancer mortality: BioBank Japan cohort

Baigent, 2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 Brugts, 2009, The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials, Br Med J, 338, b2376, 10.1136/bmj.b2376 Reiner, 2011, Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158 Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines, J Am Coll Cardiol, 63, 2889, 10.1016/j.jacc.2013.11.002 Teramoto, 2013, Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version, J Atheroscler Thromb, 20, 850, 10.5551/jat.19166 Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet, 377, 2181, 10.1016/S0140-6736(11)60739-3 Hou, 2009, Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety, Endocrinol Metab Clin North Am, 38, 79, 10.1016/j.ecl.2008.11.007 ACCORD Study Group, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, 2010, 1563 Jun, 2010, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis, Lancet, 375, 1875, 10.1016/S0140-6736(10)60656-3 Bruckert, 2010, Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis, Atherosclerosis, 210, 353, 10.1016/j.atherosclerosis.2009.12.023 Yamashita, 2009, Where are we with probucol: a new life for an old drug?, Atherosclerosis, 207, 16, 10.1016/j.atherosclerosis.2009.04.002 Kasai, 2012, Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis, Atherosclerosis, 220, 463, 10.1016/j.atherosclerosis.2011.09.051 Bucher, 2002, N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials, Am J Med, 112, 298, 10.1016/S0002-9343(01)01114-7 Balk, 2006, Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review, Atherosclerosis, 189, 19, 10.1016/j.atherosclerosis.2006.02.012 Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 Fritz, 2009, Targeting the mevalonate pathway for improved anticancer therapy, Curr Cancer Drug Targets, 9, 626, 10.2174/156800909789057033 Boudreau, 2010, Statin use and cancer risk: a comprehensive review, Expert Opin Drug Saf, 9, 603, 10.1517/14740331003662620 Nielsen, 2012, Statin use and reduced cancer-related mortality, N Engl J Med, 367, 1792, 10.1056/NEJMoa1201735 Fujimoto, 2015, Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database, Int J Med Sci, 12, 223, 10.7150/ijms.10656 Bardou, 2010, Effect of statin therapy on colorectal cancer, Gut, 59, 1572, 10.1136/gut.2009.190900 Browning, 2007, Statins and risk of cancer: a systematic review and metaanalysis, Int J Cancer, 120, 833, 10.1002/ijc.22366 Poynter, 2005, Statins and the risk of colorectal cancer, N Engl J Med, 352, 2184, 10.1056/NEJMoa043792 Dale, 2006, Statins and cancer risk: a meta-analysis, JAMA J Am Med Assoc, 295, 74, 10.1001/jama.295.1.74 Nakamura, 2007, The BioBank Japan Project, Clin Adv Hematol Oncol, 5, 696 Nagai, 2017, Overview of the BioBank Japan Project: study design and profiles, J Epidemiol, 27, S2 Hirata, 2017, Cross-sectional analysis of BioBank Japan clinical data: a large cohort of 200,000 patients with 47 common diseases, J Epidemiol, 27, S9 Hirata, 2017, Overview of BioBank Japan follow-up data in 32 diseases, J Epidemiol, 27, S22 Ministry of Internal Affairs and Communications of Japan, 2007 Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 Miller, 2010, Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures, Clin Chem, 56, 977, 10.1373/clinchem.2009.142810 Levey, 2011, The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report, Kidney Int, 80, 17, 10.1038/ki.2010.483 World Health Organization, 2004 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Mantel, 1966, Evaluation of survival data and two new rank order statistics arising in its consideration, Cancer Chemother Rep, 50, 163 Cox, 1972, Regression models and life tables (with discussion), J Roy Stat Soc, 34, 187 Prentice, 1978, The analysis of failure times in the presence of competing risks, Biometrics, 541, 10.2307/2530374 Satagopan, 2004, A note on competing risks in survival data analysis, Br J Cancer, 91, 1229, 10.1038/sj.bjc.6602102